NKGen Biotech (NYSE:NKGN) Shares Down 2.3% – Here’s Why

NKGen Biotech, Inc. (NYSE:NKGN)’s stock price was down 2.3% during mid-day trading on Monday . The stock traded as low as $0.67 and last traded at $0.70. Approximately 466,789 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 1,656,951 shares. The stock had previously closed at $0.71.

NKGen Biotech Stock Performance

The company has a market capitalization of $24.65 million, a PE ratio of -0.14 and a beta of 0.77. The firm has a fifty day simple moving average of $0.42 and a 200 day simple moving average of $0.70.

Institutional Trading of NKGen Biotech

An institutional investor recently raised its position in NKGen Biotech stock. Sequoia Financial Advisors LLC raised its stake in NKGen Biotech, Inc. (NYSE:NKGN) by 273.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,000 shares of the company’s stock after purchasing an additional 50,500 shares during the period. Sequoia Financial Advisors LLC owned 0.27% of NKGen Biotech worth $26,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 76.17% of the stock is owned by institutional investors.

NKGen Biotech Company Profile

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.